Brief: Essa Pharma Presents Updated Phase 1 Masofaniten (Epi-7386) Clinical Data
21/10/2023 17:31
Oct 21 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA PRESENTS UPDATED PHASE 1 MASOFANITEN
(EPI-7386)
CLINICAL DATA AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY 2023
CONGRESS
* ESSA PHARMA-COMBINATION OF MASOFANITEN PLUS ENZALUTAMIDE
CONTINUES TO BE WELL TOLERATED WITH DEEP AND DURABLE REDUCTIONS
IN PSA IN PATIENTS WITH MCRPC
Source text for Eikon: ID:nCNW8ZFgBa
Further company coverage: EPIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ESSA Pharma
See all newsBrief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics